ADA and severe combined immunodeficiency: In the 1990s, the landmark cure of adenosine deaminase-deficient severe combined immunodeficiency by transferring the ADA gene into T cells and hematopoietic stem and progenitor cells (HSPCs) via gene therapy in clinics led to an upsurge in gene therapy.4